News
GSK Advances mRNA Flu Vaccine to Phase III After Positive Phase II Data
GSK’s investigational mRNA seasonal flu vaccine is designed to target both haemagglutinin (HA) and neuraminidase (NA), the primary surface antigens that cause the flu virus to bind and spread.
imphoenix82
- September 1, 2026
- 0 Comments
- 168 Views
-
